OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER ‐1, UNCOVER ‐2 and UNCOVER ‐3)
Alan Menter, Richard B. Warren, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2017) Vol. 31, Iss. 10, pp. 1686-1692
Open Access | Times Cited: 71
Alan Menter, Richard B. Warren, Richard Langley, et al.
Journal of the European Academy of Dermatology and Venereology (2017) Vol. 31, Iss. 10, pp. 1686-1692
Open Access | Times Cited: 71
Showing 1-25 of 71 citing articles:
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Alan Menter, Bruce Strober, Daniel H. Kaplan, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1029-1072
Closed Access | Times Cited: 740
Alan Menter, Bruce Strober, Daniel H. Kaplan, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 4, pp. 1029-1072
Closed Access | Times Cited: 740
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 11, pp. 2461-2498
Open Access | Times Cited: 268
Alexander Nast, Catherine Smith, Phyllis I. Spuls, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 11, pp. 2461-2498
Open Access | Times Cited: 268
Old and New Biological Therapies for Psoriasis
Kirsten Rønholt, Lars Iversen
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2297-2297
Open Access | Times Cited: 218
Kirsten Rønholt, Lars Iversen
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 11, pp. 2297-2297
Open Access | Times Cited: 218
Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails
Joseph F. Merola, Abrar A. Qureshi, M. Elaine Husni
Dermatologic Therapy (2018) Vol. 31, Iss. 3
Open Access | Times Cited: 134
Joseph F. Merola, Abrar A. Qureshi, M. Elaine Husni
Dermatologic Therapy (2018) Vol. 31, Iss. 3
Open Access | Times Cited: 134
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 61
Alan Menter, Gerald G. Krueger, So Yeon Paek, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 2, pp. 385-400
Open Access | Times Cited: 61
Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
Matteo Megna, Luca Potestio, Elisa Camela, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 43
Matteo Megna, Luca Potestio, Elisa Camela, et al.
Dermatologic Therapy (2022) Vol. 35, Iss. 9
Open Access | Times Cited: 43
Role of Th17 and IL-17 Cytokines on Inflammatory and Auto-immune Diseases
Saima Akhter, Farhin Muntaha Tasnim, Mohammad Nazmul Islam, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 26, pp. 2078-2090
Closed Access | Times Cited: 28
Saima Akhter, Farhin Muntaha Tasnim, Mohammad Nazmul Islam, et al.
Current Pharmaceutical Design (2023) Vol. 29, Iss. 26, pp. 2078-2090
Closed Access | Times Cited: 28
Anti-IL17 therapies for psoriasis
Annika Silfvast‐Kaiser, So Yeon Paek, Alan Menter
Expert Opinion on Biological Therapy (2018) Vol. 19, Iss. 1, pp. 45-54
Closed Access | Times Cited: 83
Annika Silfvast‐Kaiser, So Yeon Paek, Alan Menter
Expert Opinion on Biological Therapy (2018) Vol. 19, Iss. 1, pp. 45-54
Closed Access | Times Cited: 83
Anti IL-17 in psoriasis
Karen Ly, Mary Patricia Smith, Quinn Thibodeaux, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 11, pp. 1185-1194
Closed Access | Times Cited: 75
Karen Ly, Mary Patricia Smith, Quinn Thibodeaux, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 11, pp. 1185-1194
Closed Access | Times Cited: 75
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature
Giacomo Caldarola, Federico Pirrò, Alessandro Di Stefani, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 665-672
Closed Access | Times Cited: 70
Giacomo Caldarola, Federico Pirrò, Alessandro Di Stefani, et al.
Expert Opinion on Biological Therapy (2020) Vol. 20, Iss. 6, pp. 665-672
Closed Access | Times Cited: 70
Effectiveness of ixekizumab for the treatment of moderate‐to‐severe plaque psoriasis with involvement of difficult‐to‐treat areas: A 52‐week multicenter retrospective study
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 839-843
Open Access | Times Cited: 6
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 839-843
Open Access | Times Cited: 6
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review
Isabelle M. Sanchez, Eric J. Sorenson, Ethan Levin, et al.
Dermatology and Therapy (2017) Vol. 7, Iss. 4, pp. 425-446
Open Access | Times Cited: 52
Isabelle M. Sanchez, Eric J. Sorenson, Ethan Levin, et al.
Dermatology and Therapy (2017) Vol. 7, Iss. 4, pp. 425-446
Open Access | Times Cited: 52
Manifestations and Management of Difficult-to-Treat Psoriasis
Lakshi Aldredge, Robert Higham
Journal of the Dermatology Nurses’ Association (2018) Vol. 10, Iss. 4, pp. 189-197
Open Access | Times Cited: 52
Lakshi Aldredge, Robert Higham
Journal of the Dermatology Nurses’ Association (2018) Vol. 10, Iss. 4, pp. 189-197
Open Access | Times Cited: 52
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
Luciano Ibba, Luigi Gargiulo, Ângela Alfano, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Luciano Ibba, Luigi Gargiulo, Ângela Alfano, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 14
Current therapeutic overview and future perspectives regarding the treatment of psoriasis
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113388-113388
Closed Access | Times Cited: 5
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
International Immunopharmacology (2024) Vol. 143, pp. 113388-113388
Closed Access | Times Cited: 5
Pharmacotherapeutic approaches for treating psoriasis in difficult-to-treat areas
Darío Kivelevitch, Jillian Frieder, Ian Watson, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 6, pp. 561-575
Closed Access | Times Cited: 39
Darío Kivelevitch, Jillian Frieder, Ian Watson, et al.
Expert Opinion on Pharmacotherapy (2018) Vol. 19, Iss. 6, pp. 561-575
Closed Access | Times Cited: 39
Sustained efficacy of secukinumab in patients with moderate‐to‐severe palmoplantar psoriasis: 2·5‐year results from GESTURE , a randomized, double‐blind, placebo‐controlled trial
Alice B. Gottlieb, А. А. Кубанов, Martijn B. A. van Doorn, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 4, pp. 889-899
Closed Access | Times Cited: 37
Alice B. Gottlieb, А. А. Кубанов, Martijn B. A. van Doorn, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 4, pp. 889-899
Closed Access | Times Cited: 37
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian Study
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Dermatology and Therapy (2025)
Open Access
Federico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Dermatology and Therapy (2025)
Open Access
Incidence of therapy switch in patients with moderate to severe palmoplantar psoriasis treated with anti-il 17 and anti-il 23 monoclonal antibodies: a retrospective observational study
Alessandra Michelucci, Flavia Manzo Margiotta, Filippo Fanetti, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Alessandra Michelucci, Flavia Manzo Margiotta, Filippo Fanetti, et al.
Expert Opinion on Biological Therapy (2025)
Closed Access
Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis
Abdullah Demirbaş, Esin Diremsizoğlu, Mustafa Esen, et al.
Postgraduate Medicine (2025)
Closed Access
Abdullah Demirbaş, Esin Diremsizoğlu, Mustafa Esen, et al.
Postgraduate Medicine (2025)
Closed Access
Ixekizumab for the treatment of psoriasis: an update on new data since first approval
C. Blegvad, Lone Skov, Claus Zachariae
Expert Review of Clinical Immunology (2018) Vol. 15, Iss. 2, pp. 111-121
Closed Access | Times Cited: 32
C. Blegvad, Lone Skov, Claus Zachariae
Expert Review of Clinical Immunology (2018) Vol. 15, Iss. 2, pp. 111-121
Closed Access | Times Cited: 32
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis
I‐Hsin Huang, Po‐Chien Wu, Hsien‐Yi Chiu, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 3, pp. 347-358
Closed Access | Times Cited: 3
I‐Hsin Huang, Po‐Chien Wu, Hsien‐Yi Chiu, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 3, pp. 347-358
Closed Access | Times Cited: 3
Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
Antibodies (2024) Vol. 13, Iss. 3, pp. 76-76
Open Access | Times Cited: 3
Francesco Ferrara, Chiara Verduci, Emanuela Laconi, et al.
Antibodies (2024) Vol. 13, Iss. 3, pp. 76-76
Open Access | Times Cited: 3
<p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p>
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Patient Preference and Adherence (2020) Vol. Volume 14, pp. 517-527
Open Access | Times Cited: 23
Andrew Blauvelt, Nianwen Shi, Russel Burge, et al.
Patient Preference and Adherence (2020) Vol. Volume 14, pp. 517-527
Open Access | Times Cited: 23
Comparative study of the efficacy and safety of secukinumab vs ixekizumab in moderate‐to‐severe psoriasis after 1 year of treatment: Real‐world practice
Enrique Herrera‐Acosta, Gustavo Guillermo Garriga‐Martina, Jorge Alonso Suárez‐Pérez, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 23
Enrique Herrera‐Acosta, Gustavo Guillermo Garriga‐Martina, Jorge Alonso Suárez‐Pérez, et al.
Dermatologic Therapy (2020) Vol. 33, Iss. 3
Open Access | Times Cited: 23
